LGALS9 and neoplasm: Accordingly, holistic integration of preclinical and clinical trial data pertaining to Gal-9 tumor immunobiological functions, therapeutic outcomes, and drug safety will be important considerations in harnessing and optimizing the cancer therapeutic potential of the Gal-9 glyco-immune checkpoint axis.